Andrew David Levin - 05 Jun 2026 Form 4 Insider Report for Climb Bio, Inc. (CLYM)

Reporting relationship: Director
Issuer ticker: CLYM
Reported as of: 05 Jun 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 08 Jun 2026, 18:42:01 UTC
Prior SEC filing: 19 Dec 2025
Next SEC filing: 12 Jun 2026
Source filing: View source filing
Reporting owner signature: Chandra Adams, as Attorney-in-Fact

Key filing fact

Andrew David Levin filed Form 4 for Climb Bio, Inc. (CLYM) on 08 Jun 2026.

Key facts

This page summarizes Andrew David Levin's Form 4 filing for Climb Bio, Inc. (CLYM).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 08 Jun 2026, 18:42.

Change

Previous filing in this sequence was filed on 19 Dec 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001867539 Primary reporting owner

Levin Andrew David

Relationship: Director
Address: C/O CLIMB BIO, INC., 20 WILLIAM STREET, SUITE 145, WELLESLEY HILLS
Signature: Chandra Adams, as Attorney-in-Fact
Signature date: 08 Jun 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CLYM transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +40,000
Change %
Price: $0.000000^*
Shares after: 40,000
Date: 05 Jun 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 40,000
Exercise price: $10.55
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The shares subject to the option will vest on the earlier of June 5, 2027 or the date immediately prior to the date of the next annual meeting of stockholders, subject to the reporting person's continued service through such date.

Footnote F2

Under the reporting person's arrangement with RA Capital Management, L.P. (the "Adviser"), the reporting person holds the stock option for the benefit of the RA Capital Healthcare Fund, L.P. (the "Fund"), RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"), RA Capital Nexus Fund III, L.P. (the "Nexus Fund III"), and a separately managed account (the "Account"). The reporting person is obligated to turn over to the Adviser any net cash or stock received upon exercise of the stock option, which will offset advisory fees owed by the Fund, the Nexus Fund, the Nexus Fund II, the Nexus Fund III, and the Account to the Adviser. The reporting person therefore disclaims beneficial ownership of the stock option and underlying common stock.